Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed Chronic Lymphocytic Lymphoma Patients

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35845010

Authors

Namrata Singh

Sarah L Mott

Grerk Sutamtewagul

Ashley McCarthy

Susan L Slager

James R Cerhan

Zuhair Ballas

Brian K Link

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the prevalence of hypogammaglobulinemia in chronic lymphocytic lymphoma (CLL) patients and to test the hypothesis that patients with hypogammaglobulinemia have a distinct clinical profile and outcome.

Methods: Immunoglobulin levels (IgA, IgG, IgM, IgE) were measured in newly diagnosed, treatment naïve banked samples of 150 patients with CLL followed prospectively for outcomes. Cox regression models were used to assess the effects of clinical variables on overall survival (OS).

Results: The median age of the selected CLL cohort was 64 years with a male predominance; 96.2% of the patients were white. Fifty-nine deaths occurred during a median follow up of 6.8 years. Hypogammaglobulinemia in CLL was common in our cohort with 88 (58.7%, 95% CI: 50.4-66.6%) patients having a measurable isotype deficiency. The most common Ig deficiency was IgM (44.0%). IgA deficiency or low IgE was associated with higher Rai stages as well as with higher white blood cell counts at presentation. Any immunoglobulin deficiency was not associated with overall survival.

Conclusion: A significant proportion of treatment-naïve CLL patients had underlying Ig deficiencies - both in isolation and in isotype combinations. Although a deficiency of IgA or IgE was associated with more severe disease at presentation, the impact of this association was mild.

Citing Articles

Call for Balancing the Risks and Benefits of Immunotherapeutic Agents for Lymphoma during the COVID-19 Pandemic.

Lee C, Beom Park W Infect Chemother. 2024; 56(3):406-408.

PMID: 39370126 PMC: 11458502. DOI: 10.3947/ic.2024.0105.

Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy.

Vodarek P, Ecsiova D, Rezacova V, Soucek O, Simkovic M, Vokurkova D Cancer Med. 2024; 13(15):e7399.

PMID: 39119792 PMC: 11310768. DOI: 10.1002/cam4.7399.

Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis.

Murru R, Galitzia A, Barabino L, Presicci R, La Nasa G, Caocci G Ann Hematol. 2024; 103(5):1655-1664.

PMID: 38236391 PMC: 11009768. DOI: 10.1007/s00277-024-05625-y.

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients.

Singh N, Mott S, Sutamtewagul G, McCarthy A, Slager S, Cerhan J EJHaem. 2022; 1(2):537-544.

PMID: 35845010 PMC: 9176078. DOI: 10.1002/jha2.95.

References

Unsworth D, Virgo P, Lock R . Immunoglobulin E deficiency: a forgotten clue pointing to possible immunodeficiency?. Ann Clin Biochem. 2011; 48(Pt 5):459-61. DOI: 10.1258/acb.2011.011052. View

Heaney J, Campbell J, Iqbal G, Cairns D, Richter A, Child J . Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018; 32(8):1727-1738. PMC: 6087716. DOI: 10.1038/s41375-018-0163-4. View

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760. DOI: 10.1182/blood-2017-09-806398. View

Strati P, Parikh S, Chaffee K, Kay N, Call T, Achenbach S . Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017; 178(3):394-402. PMC: 6377071. DOI: 10.1111/bjh.14785. View

Ben-Bassat I, Many A, Modan M, Peretz C, Ramot B . Serum immunoglobulins in chronic lymphocytic leukemia. Am J Med Sci. 1979; 278(1):4-9. DOI: 10.1097/00000441-197907000-00001. View

Cheson B, Bennett J, Grever M, Kay N, Keating M, OBrien S . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87(12):4990-7. View

Morrison V . Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma. 2009; 9(5):365-70. DOI: 10.3816/CLM.2009.n.071. View

Wadhwa P, Morrison V . Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006; 33(2):240-9. DOI: 10.1053/j.seminoncol.2005.12.013. View

Ishdorj G, Streu E, Lambert P, Dhaliwal H, Mahmud S, Gibson S . IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv. 2019; 3(14):2188-2198. PMC: 6650736. DOI: 10.1182/bloodadvances.2018026591. View

10.

Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y . Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. Eur J Haematol. 2014; 93(1):29-33. DOI: 10.1111/ejh.12290. View

11.

Da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann C . Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016; 6(11):e499. PMC: 5148052. DOI: 10.1038/bcj.2016.105. View

12.

Freeman J, Crassini K, Best O, Forsyth C, Mackinlay N, Han P . Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012; 54(1):99-104. DOI: 10.3109/10428194.2012.706285. View

13.

Andersen M, Vojdeman F, Klarskov Andersen M, de Nully Brown P, Geisler C, Bjerrum O . Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016; 57(7):1592-9. DOI: 10.3109/10428194.2016.1142082. View

14.

Parikh S, Leis J, Chaffee K, Call T, Hanson C, Ding W . Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer. 2015; 121(17):2883-91. PMC: 4545721. DOI: 10.1002/cncr.29438. View

15.

Svensson T, Hoglund M, Cherif H . Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. Scand J Infect Dis. 2013; 45(7):537-42. DOI: 10.3109/00365548.2013.769279. View

16.

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View

17.

Salzer U, Warnatz K, Peter H . Common variable immunodeficiency: an update. Arthritis Res Ther. 2012; 14(5):223. PMC: 3580506. DOI: 10.1186/ar4032. View

18.

Smith J, Krishnaswamy G, Dykes R, Reynolds S, Berk S . Clinical manifestations of IgE hypogammaglobulinemia. Ann Allergy Asthma Immunol. 1997; 78(3):313-8. DOI: 10.1016/S1081-1206(10)63188-2. View

19.

Singh N, Mott S, Sutamtewagul G, McCarthy A, Slager S, Cerhan J . Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem. 2022; 1(2):537-544. PMC: 9176078. DOI: 10.1002/jha2.95. View

20.

Tadmor T, Braester A, Najib D, Aviv A, Herishanu Y, Yuklea M . A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain. Eur J Haematol. 2019; 103(4):335-341. DOI: 10.1111/ejh.13288. View